Glenmark Pharma

Why is Glenmark Pharmaceuticals Ltd. falling/rising?

As of 26-Aug, Glenmark Pharmaceuticals Ltd. is seeing a stock price increase to 2,440.00, up 1.88%. This rise is driven by strong performance metrics, increased investor interest, and favorable financial ratios, significantly outperforming the benchmark Sensex.

As of 26-Aug, Glenmark Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 2,440.00, reflecting an increase of 45.0 (1.88%). This upward movement can be attributed to several positive factors. The stock has outperformed the benchmark Sensex, with a weekly return of +8.20% compared to the Sensex's +0.73%. Over the past month, Glenmark has shown an impressive return of +11.25%, while the Sensex has only increased by +1.86%. Year-to-date, the stock has gained +19.85%, significantly outperforming the Sensex, which is down -9.09%.<BR><BR>Additionally, Glenmark's stock is close to its 52-week high, just 1.27% away from Rs 2,471.05, and has been on a consecutive gain streak for the last three days, accumulating a total return of 5.81% during this period. The stock reached an intraday high of Rs 2,457.85, marking a rise of 2.62% for the day. It is also trading above its moving averages across various time frames, indicating a strong bullish trend.<BR><BR>Investor participation has increased, with a delivery volume of 2.9 lacs on August 25, which is up by 10.56% compared to the five-day average, suggesting growing interest in the stock. Furthermore, Glenmark has a low Debt to EBITDA ratio of 0.13 times, indicating a strong ability to service its debt, and a high return on equity (ROE) of 26.9, which contributes to its attractive valuation. The stock is trading at a discount relative to its peers, and its profits have risen significantly, with a PEG ratio of 0.1.<BR><BR>Overall, the combination of strong performance metrics, increasing investor interest, and favorable financial ratios contributes to the rising stock price of Glenmark Pharmaceuticals Ltd.

Which are the latest news on Glenmark Pharma?

Should I buy, sell or hold Glenmark Pharmaceuticals Ltd.?

Who are in the management team of Glenmark Pharma?

The management team of Glenmark Pharma includes Glenn Saldanha (Chairman/Executive Director), Cheryl Pinto (Executive Director), and V S Mani (Executive Director & Group CFO), along with several independent and non-executive directors who provide diverse expertise for the company's governance.

The management team of Glenmark Pharma includes the following key members:<BR><BR>1. **Glenn Saldanha** - Chairman / Executive Director<BR>2. **Cheryl Pinto** - Executive Director (Corporate)<BR>3. **V S Mani** - Executive Director & Group CFO<BR><BR>Additionally, the board features several independent and non-executive directors:<BR><BR>- **B E Saldanha** - Non-Executive Director<BR>- **Rajesh Desai** - Independent Non-Executive Director<BR>- **Devendra Raj Mehta** - Independent Non-Executive Director<BR>- **Bernard Munos** - Independent Non-Executive Director<BR>- **Brian W Tempest** - Independent Non-Executive Director<BR>- **Sridhar Gorthi** - Independent Non-Executive Director<BR>- **Sona Saira Ramasastry** - Independent Non-Executive Director<BR>- **Dipankar Bhattacharjee** - Independent Non-Executive Director<BR>- **V R Iyer** - Independent Non-Executive Director<BR><BR>This team brings a diverse range of expertise to the company, contributing to its strategic direction and governance.

What does Glenmark Pharma do?

Glenmark Pharmaceuticals Ltd. is a mid-cap company engaged in the discovery, development, manufacture, and marketing of pharmaceutical products. As of June 2026, it reported net sales of 4,018 Cr and a net profit of 483 Cr, with a market cap of INR 64,941 Cr.

Overview:<BR>Glenmark Pharmaceuticals Ltd. is a mid-cap company in the Pharmaceuticals & Biotechnology industry, focused on the discovery, development, manufacture, and marketing of pharmaceutical products.<BR><BR>History:<BR>Glenmark Pharmaceuticals Ltd. was incorporated on November 18th, 1977. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 4,018 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 483 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 64,941 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 21.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.22%<BR>- Debt-Equity: -0.06<BR>- Return on Equity: 26.86%<BR>- Price to Book: 6.10<BR><BR>Contact Details:<BR>- Address: B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra: 400026<BR>- Tel: 91-22-40189999<BR>- Email: complianceofficer@glenmarkpharma.co<BR>- Website: http://www.glenmarkpharma.com

Who are the peers of the Glenmark Pharma?

Glenmark Pharma's peers include Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, Biocon, Alkem Lab, Abbott India, Anthem Bioscienc, Gland Pharma, and Ipca Labs. In terms of performance, Laurus Labs leads with a 1-year return of 113.22%, while Glenmark Pharma has a return of 12.92%.

Peers: Glenmark Pharma's peers include Laurus Labs, Dr Reddy's Labs, Aurobindo Pharma, Biocon, Alkem Lab, Abbott India, Anthem Bioscienc, Gland Pharma, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Reddy's Labs and Abbott India, while Good management risk is found at Laurus Labs, Alkem Lab, Anthem Bioscienc, Gland Pharma, Ipca Labs, and Glenmark Pharma, and Average management risk is noted at Aurobindo Pharma and Biocon. For Growth, Excellent growth is seen at Anthem Bioscienc, Average growth at Dr Reddy's Labs and Abbott India, and Below Average growth at Laurus Labs, Aurobindo Pharma, Alkem Lab, Biocon, Gland Pharma, and Ipca Labs. In terms of Capital Structure, Excellent capital structure is noted at Dr Reddy's Labs, Aurobindo Pharma, Alkem Lab, Abbott India, Anthem Bioscienc, Gland Pharma, and Ipca Labs, while Glenmark Pharma has a Good capital structure and Laurus Labs, Biocon, and Alkem Lab have an Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Laurus Labs at 113.22%, while Abbott India has the lowest at -16.28%. Glenmark Pharma's 1-year return of 12.92% is higher than Abbott India's but lower than Laurus Labs'. Additionally, Abbott India and Dr Reddy's Labs have negative six-month returns.

How big is Glenmark Pharma?

As of 14th August, Glenmark Pharmaceuticals Ltd. has a market capitalization of 65,550.00 Cr, with net sales of 17,736.56 Cr and a net profit of 1,797.89 Cr over the latest four quarters.

As of 14th August, <BR><BR>Market Cap: Glenmark Pharmaceuticals Ltd. has a market capitalization of 65,550.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 17,736.56 Cr, while the sum of Net Profit for the same period is 1,797.89 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 8,849.44 Cr, and Total Assets amount to 14,925.44 Cr.

When is the next results date for Glenmark Pharmaceuticals Ltd.?

The next results date for Glenmark Pharmaceuticals Ltd. is 31 July 2026.

The next results date for Glenmark Pharmaceuticals Ltd. is scheduled for 31 July 2026.

Are Glenmark Pharmaceuticals Ltd. latest results good or bad?

Glenmark Pharmaceuticals Ltd.'s latest results show strong year-on-year growth with a net profit increase of 6,381.94% and net sales up 15.80%. However, there are concerns due to sequential declines in both profit and sales, indicating potential volatility in performance.

Glenmark Pharmaceuticals Ltd.'s latest results present a mixed picture. For the quarter ending March 2026, the company reported a net profit of ₹301.41 crores, which reflects a significant year-on-year increase of 6,381.94%. However, this represents a decline of 25.25% compared to the previous quarter, raising concerns about the sustainability of its recent performance.<BR><BR>Net sales for the same quarter were ₹3,770.59 crores, showing a 15.80% increase year-on-year, but a decrease of 3.33% from the previous quarter. This sequential decline follows an unusually strong performance in Q3 FY26, which had benefited from one-time gains.<BR><BR>Operating margins also contracted to 20.28%, down from 22.37% in the previous quarter, indicating some pressure on profitability. Despite these challenges, the company's return on capital employed (ROCE) reached an impressive 40.16%, the highest level recorded in recent periods, suggesting strong operational efficiency.<BR><BR>Overall, while Glenmark's year-on-year growth is commendable, the sequential declines in both net profit and sales indicate potential volatility and questions about the underlying business momentum. Investors may want to consider these factors when evaluating the company's performance.

Is Glenmark Pharma overvalued or undervalued?

As of November 17, 2025, Glenmark Pharma is considered undervalued with a PE ratio of 23.47 and strong growth potential, outperforming peers like Sun Pharma and Cipla, and has delivered a 21.44% return over the past year compared to the Sensex's 9.50%.

As of 17 November 2025, Glenmark Pharma's valuation grade has moved from expensive to attractive, indicating a shift in market perception. The company is currently considered undervalued. Key ratios supporting this assessment include a PE ratio of 23.47, an EV to EBITDA of 12.50, and a PEG ratio of 0.04, which suggests strong growth potential relative to its price.<BR><BR>In comparison to its peers, Glenmark Pharma's valuation metrics stand out; for instance, Sun Pharma has a significantly higher PE ratio of 36.69, while Cipla, another attractive peer, has a PE of 22.81. This positions Glenmark favorably within the industry, particularly given its robust ROCE of 44.14% and ROE of 23.46%. Additionally, Glenmark's stock has outperformed the Sensex over the past year, with a return of 21.44% compared to the Sensex's 9.50%, reinforcing the attractiveness of its current valuation.

How has been the historical performance of Glenmark Pharma?

Glenmark Pharma's historical performance shows significant fluctuations, with net sales increasing to 13,321.74 Cr in Mar'25 after a dip in Mar'23, and a recovery in profit after tax to 1,047.14 Cr in Mar'25 from a loss of 1,830.85 Cr in the previous year. Despite negative cash flow from operating activities in Mar'25, the company demonstrates a recovery trajectory following a challenging period.

Answer:<BR>The historical performance of Glenmark Pharma shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Glenmark Pharma's net sales increased from 10,640.97 Cr in Mar'20 to 13,321.74 Cr in Mar'25, with a notable dip in Mar'23 at 12,990.11 Cr. Total operating income followed a similar trend, reaching 13,321.74 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 8,279.66 Cr in Mar'19 to 10,970.36 Cr in Mar'25. Operating profit (PBDIT) saw fluctuations, peaking at 2,595.16 Cr in Mar'23 before declining to 2,465.10 Cr in Mar'25. Profit before tax was 1,399.21 Cr in Mar'25, recovering from a low of 36.50 Cr in Mar'24. The profit after tax turned positive at 1,047.14 Cr in Mar'25 after a significant loss of 1,830.85 Cr in the previous year. The earnings per share (EPS) rebounded to 37.1 in Mar'25 from a negative EPS of -53.21 in Mar'24. Total assets increased to 14,925.44 Cr in Mar'25, while total liabilities also rose to 14,925.44 Cr, indicating a balanced growth in the company’s financial structure. Cash flow from operating activities was negative at -827.00 Cr in Mar'25, contrasting with a positive cash flow of 782.00 Cr in Mar'24. Overall, Glenmark Pharma's financial performance reflects a recovery trajectory in 2025 after a challenging previous year.

Is Glenmark Pharma technically bullish or bearish?

As of September 10, 2025, Glenmark Pharma's trend is mildly bullish, supported by daily moving averages and weekly Bollinger Bands, but tempered by mixed signals from the MACD and OBV.

As of 10 September 2025, the technical trend for Glenmark Pharma has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullish momentum and the weekly Bollinger Bands also showing bullish signals. However, the weekly MACD is mildly bearish and the KST is bullish on a weekly basis but mildly bearish on a monthly basis, suggesting some mixed signals. The Dow Theory indicates a mildly bullish stance on the weekly chart, while the OBV shows a mildly bearish trend. Overall, the strength of the bullish sentiment is tempered by the mixed indicators, particularly on the weekly timeframe.

Who are the top shareholders of the Glenmark Pharma?

The top shareholders of Glenmark Pharma include the Saldanha Family Trust with 45.45%, institutional investors holding 36.02% (including 25 mutual fund schemes at 12.86% and 347 FIIs at 23.16%), and individual investors with 12.32%. HDFC Mutual Fund is the largest public shareholder with a 4.27% stake.

The top shareholders of Glenmark Pharma include the Saldanha Family Trust, which holds the largest stake at 45.45%. The company also has significant institutional backing, with 25 mutual fund schemes collectively holding 12.86% and 347 foreign institutional investors (FIIs) holding 23.16%. Additionally, HDFC Mutual Fund, specifically through the HDFC Nifty Large Midcap 250 Index fund, is the highest public shareholder with a 4.27% stake. Individual investors collectively own 12.32% of the company.

Has Glenmark Pharma declared dividend?

Yes, Glenmark Pharmaceuticals has declared a 250% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company has shown strong total returns over various periods, particularly in the long term.

Glenmark Pharmaceuticals Ltd. has declared a 250% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: 13 Sep 24<BR><BR>Dividend Yield: 0.16%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 3.97%, with no dividend return, resulting in a total return of 3.97%.<BR><BR>Over the past year, the price return was 31.68%, with a dividend return of 0.21%, leading to a total return of 31.89%.<BR><BR>In the 2-year period, the price return was 152.58%, with a dividend return of 0.78%, culminating in a total return of 153.36%.<BR><BR>For the 3-year period, the price return was 305.84%, with a dividend return of 2.04%, resulting in a total return of 307.88%.<BR><BR>In the last 4 years, the price return was 159.41%, with a dividend return of 1.50%, giving a total return of 160.91%.<BR><BR>Over the 5-year period, the price return was 295.81%, with a dividend return of 2.87%, leading to a total return of 298.68%.<BR><BR>Overall, Glenmark Pharma has declared a substantial dividend, and the total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting a positive performance trend for the company.